Epitinib|CAS 1203902-67-3|DC Chemicals

Cas No.:	1203902-67-3
Chemical Name:	4-Ethyl-N-4-(3-ethynylphenyl)amino-7-methoxy-6-quinazolinyl-1-piperazinecarboxamide
Synonyms:	Epitinib;Epitinib [WHO-DD];WZ97ZE4UUG;4-ethyl-N-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide;4-Ethyl-N-(4-((3-ethynylphenyl)amino)-7-methoxy-6-quinazolinyl)-1-piperazinecarboxamide;HMPL813;GTPL11608;compound 68 [WO2010002845A2];D96105;4-ETHYL-N-{4-[(3-ETHYNYLPHENYL)AMINO]-7-METHOXYQUINAZOLIN-6-YLPIPERAZINE-1-CARBOXAMIDE;4-ethyl-N-(4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)piperazine-1-carboxamide;EOS-61549;1-Piperazinecarboxamide, 4-ethyl-N-[4-[(3-ethynylphenyl)amino]-7-methoxy-6-quinazolinyl]-;HMPL-813
SMILES:	O=C(NC1C(=CC2C(=C(N=CN=2)NC2C=CC=C(C#C)C=2)C=1)OC)N1CCN(CC)CC1
Formula:	C₂₄H₂₆N₆O₂
M.Wt:	430.502244472504
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

COA

MSDS

Cat. No.	Product name	Field of application
DC57050	DZD9008	DZD9008 is an oral, potent, irreversible, wild type-selective EGFR TKI against EGFR or HER2 Exon20ins and other mutations.
DC74400	OBX02-011	OBX02-011 is a potent, reversible, fourth-generation EGFR tyrosine kinase inhibitor (TKI) that overcomes the EGFR C797S mutation, inhibits triple mutants Del19/T790M/C797S and L858R/T790M/C797S with IC50 of 0.134 and 2.09 nM, respectively.
DC74398	HSL119	HSL119 is a highly effective and selective inhibitor of hormonally upregulated neu-associated kinase (HUNK), demonstrating complete suppression of HUNK kinase activity at a concentration of 1 µM in biochemical assays. This compound highlights its precision and potency in targeting HUNK.
DC74394	DSF-102	DSF-102 (DSF102) is a small molecule EGFR inhibitor that interacts with the extracellular domain (ECD) of EGFR, inhibits the interaction with the EGF instead of blocking the intracellular kinase activity, shows inhibition of EGFR dimerization with IC50 of
DC74393	BI-8128	BI-8128 is a potent, selective, reversible and orally bioavailable fourth generation EGFR inhibitor, potently inhibits oncogenic EGFR variants del19 and L858R as well as the acquired EGFR resistance mutations T790M and C797S.
DC70170	AC3573	AC3573 (AC-3573) is a potent, specific small molecule inhibitor of HER3.AC3573 abrogates HER2–HER3 signalling in cells and is more specific for HER3, inhibits NRG (heregulin)-induced HER3 phosphorylation with IC50 of 10 uM, abrogates the formation of the active HER2-HER3 heterodimer, inhibits oncogenic downstream signalling in SK-BR-3 breast cancer cells.
DC46930	Sunvozertinib	Sunvozertinib is a potent inhibitor targeting the ErbB family of receptor tyrosine kinases, including EGFR (Epidermal Growth Factor Receptor) and Her2 (Human Epidermal Growth Factor Receptor 2), as well as BTK (Bruton's Tyrosine Kinase). It exhibits particularly strong activity against mutant forms of these kinases, which are often associated with resistance to existing therapies in cancers such as non-small cell lung cancer (NSCLC). The IC50 values (half-maximal inhibitory concentr.
DC46163	Epitinib	Epitinib is an orally active and selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) designed for optimal brain penetration. Epitinib can be used for the research of cancer.
DC45794	Tucatinib hemiethanolate	Tucatinib (Irbinitinib) hemiethanolate is a potent, orally active and selective HER2 inhibitor with an IC50 of 8 nM.
DC45317	EGFR/ErbB-2/ErbB-4 inhibitor-2	EGFR/ErbB-2/ErbB-4 inhibitor-2 (Compound 5) is a EGFR and ErbB inhibitor with IC50s of 0.017 μM, 0.08 μM, 1.91 μM.